Amyris, Inc.
PrivateLast Round
Debt
Feb 2, 2024
Est. Valuation
$644.73M
Total Funding Raised
$1.51B
Company Overview
Amyris, Inc. is a synthetic biotechnology company that develops and manufactures sustainable ingredients for the health and wellness, clean beauty, and flavor and fragrance markets.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Sustainable Materials, Clean Manufacturing
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amyris, Inc. Comparables
Compare Amyris, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Conagen | 81% | |
| Manus Bio | 78% | |
| Geltor | 78% |
Amyris, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Feb 2, 2024 | ||||
| Bankruptcy | Aug 9, 2023 | ||||
| Private Placement | Dec 29, 2022 | ||||
| Debt | Oct 11, 2022 | ||||
| Debt | Sep 13, 2022 | ||||
Convertible Debt | Nov 15, 2021 |
Key People
Founding team and executive leadership
Amyris, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Temasek | Series D, Convertible Debt |
| Cowen Private Investments | Follow-on Offering |
| The Westly Group | Series D |
| Khosla Ventures | Series B, Series C, Series D, Series A |
| Stifel, Nicolaus & Company, Incorporated | IPO |
| Wolverine Asset Management | Convertible Debt |
| Morgan Stanley | IPO |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 4, 2025
Monthly visitors increased 62% MoM, reaching 9.9K.
- Feb 2, 2024
$160M debt round completed.
Amyris, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Amyris, Inc.'s valuation, stock price, and market status.
Is Amyris, Inc. a public or private company?
Amyris, Inc. is a private company.
What is the current stock price of Amyris, Inc.?
Amyris, Inc. is a private company, so its shares have no public market price. Caplight tracks Amyris, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Amyris, Inc. worth (valuation)?
Amyris, Inc.'s valuation is estimated at $644.7M based on funding round data.
Can I buy Amyris, Inc. stock?
Amyris, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Amyris, Inc.'s last funding round?
Amyris, Inc.'s most recent funding round was Debt on February 2, 2024.
Who are the main investors in Amyris, Inc.?
Key investors in Amyris, Inc. include Temasek, Cowen Private Investments, Khosla Ventures, Morgan Stanley, Bill & Melinda Gates Foundation.
Will Amyris, Inc. IPO soon?
No public IPO plans have been announced for Amyris, Inc..
How can I track Amyris, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Amyris, Inc.'s shares on secondary markets.